703 related articles for article (PubMed ID: 25880495)
1. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy.
Tao W; Zeng X; Liu T; Wang Z; Xiong Q; Ouyang C; Huang L; Mei L
Acta Biomater; 2013 Nov; 9(11):8910-20. PubMed ID: 23816645
[TBL] [Abstract][Full Text] [Related]
3. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
6. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
[TBL] [Abstract][Full Text] [Related]
7. Preparation and Characterization of PLGA-PEG-PLGA Nanoparticles Containing Salidroside and Tamoxifen for Breast Cancer Therapy.
Yu X; Sun L; Tan L; Wang M; Ren X; Pi J; Jiang M; Li N
AAPS PharmSciTech; 2020 Jan; 21(3):85. PubMed ID: 31997020
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.
Chen J; Li S; Shen Q; He H; Zhang Y
Drug Dev Ind Pharm; 2011 Nov; 37(11):1339-46. PubMed ID: 21524153
[TBL] [Abstract][Full Text] [Related]
9. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
10. Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.
Fan P; Cunliffe HE; Griffith OL; Agboke FA; Ramos P; Gray JW; Jordan VC
Eur J Cancer; 2014 Nov; 50(16):2877-86. PubMed ID: 25212499
[TBL] [Abstract][Full Text] [Related]
11. Pigment epithelial-derived factor gene loaded novel COOH-PEG-PLGA-COOH nanoparticles promoted tumor suppression by systemic administration.
Yu T; Xu B; He L; Xia S; Chen Y; Zeng J; Liu Y; Li S; Tan X; Ren K; Yao S; Song X
Int J Nanomedicine; 2016; 11():743-59. PubMed ID: 26955272
[TBL] [Abstract][Full Text] [Related]
12. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
Jiang SY; Langan-Fahey SM; Stella AL; McCague R; Jordan VC
Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
[TBL] [Abstract][Full Text] [Related]
13. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
Essa S; Rabanel JM; Hildgen P
Int J Pharm; 2011 Jun; 411(1-2):178-87. PubMed ID: 21458551
[TBL] [Abstract][Full Text] [Related]
14. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
15. Andrographolide-loaded PLGA-PEG-PLGA micelles to improve its bioavailability and anticancer efficacy.
Zhang J; Li Y; Gao W; Repka MA; Wang Y; Chen M
Expert Opin Drug Deliv; 2014 Sep; 11(9):1367-80. PubMed ID: 24935153
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
17. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants.
Pawlik A; Słomińska-Wojewódzka M; Herman-Antosiewicz A
Eur J Nutr; 2016 Apr; 55(3):1165-80. PubMed ID: 26014809
[TBL] [Abstract][Full Text] [Related]
19. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity.
Singh R; Kesharwani P; Mehra NK; Singh S; Banerjee S; Jain NK
Drug Dev Ind Pharm; 2015; 41(11):1888-901. PubMed ID: 25738812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
